secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001171843-25-002401
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus announces five abstracts on imdusiran and AB-101 accepted at EASL 2025, including late-breaker
--------------------------------------------------------------------------------

- Five abstracts accepted for poster presentation at EASL Congress 2025 (May 7-10, Amsterdam); one late-breaker (LB25153).
- Abstract 1768: IM-PROVE I study shows HBsAg at baseline and NA discontinuation associated with functional cure in CHB subjects.
- Abstract 2043: Rapid HBV RNA decline during imdusiran lead-in, then transient increases with interferon, linked to HBsAg seroclearance.
- AB-101 (oral PD-L1 inhibitor) data: well-tolerated in healthy/subjects, dose-responsive PD-L1 RO, high liver biodistribution.
- Late-breaker LB25153: off-treatment antiviral efficacy and safety of repeat imdusiran + VTP-300 with/without nivolumab in CHB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325002401/0001171843-25-002401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325002401/f8k_042325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer